By Abigail Hisler, Director, Strategic Marketing, Global Biologics, and Olga Laskina, Manager, Analytical Services, Glass Systems
The number of approved biologics is helping to grow the treatment options available to patients. Emerging companies are driving this growth through the development of new molecules that are at the heart of impressive leaps in medical innovation.
Emerging companies are small or newly formed organizations and have unique challenges compared to larger biologic companies. They need access to adequate funding, are heavily reliant on outsourcing, and have limited resources to support many of the activities needed to bring a drug to market. While emerging companies are smaller in size and may face different obstacles than larger and more experienced companies, these segments share two common objectives for drug development: overall speed to market and regulatory approval.
Access this white paper which reviews dynamics in bringing an injectable biologic to market and focuses on the top challenges that emerging companies face. This paper will provide solutions on how to set your small company up for long-term success using packaging containment offerings and services to help mitigate risks and speed up your time to market.